Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma
Paolo Strati, Loretta J. Nastoupil, Jason R. Westin, et al.
Blood Advances (2020) Vol. 4, Iss. 16, pp. 3943-3951
Open Access | Times Cited: 86

Showing 1-25 of 86 citing articles:

CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma
Kai Rejeski, Ariel Perez Perez, Pierre Sesques, et al.
Blood (2021) Vol. 138, Iss. 24, pp. 2499-2513
Open Access | Times Cited: 292
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma
Paolo Strati, Sairah Ahmed, Fateeha Furqan, et al.
Blood (2021) Vol. 137, Iss. 23, pp. 3272-3276
Open Access | Times Cited: 162
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma
Olalekan O. Oluwole, Krimo Bouabdallah, Javier Muñoz, et al.
British Journal of Haematology (2021) Vol. 194, Iss. 4, pp. 690-700
Open Access | Times Cited: 147
Corticosteroids and Cancer Immunotherapy
Rachel Goodman, Douglas B. Johnson, Justin M. Balko
Clinical Cancer Research (2023) Vol. 29, Iss. 14, pp. 2580-2587
Closed Access | Times Cited: 52
Immunotherapy on ICU: a narrative review
S.K. Carter, Timothy Wigmore
Anaesthesia (2025)
Open Access | Times Cited: 2
CRP and ferritin in addition to the EASIX score predict CAR-T–related toxicity
Uri Greenbaum, Paolo Strati, Rima M. Saliba, et al.
Blood Advances (2021) Vol. 5, Iss. 14, pp. 2799-2806
Open Access | Times Cited: 93
Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review
Shakira J. Grant, Alyssa Grimshaw, Juliet Silberstein, et al.
Transplantation and Cellular Therapy (2022) Vol. 28, Iss. 6, pp. 294-302
Open Access | Times Cited: 67
Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy
Robert C. Sterner, Rosalie M. Sterner
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 51
CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: Is it still a concern?
Roser Velasco, Alberto Mussetti, Macarena Villagrán‐García, et al.
Frontiers in Neurology (2023) Vol. 14
Open Access | Times Cited: 27
EEG before chimeric antigen receptor T-cell therapy and early after onset of immune effector cell-associated neurotoxicity syndrome
Rafael Hernani, Mika Aiko, Ruth Victorio, et al.
Clinical Neurophysiology (2024) Vol. 163, pp. 132-142
Open Access | Times Cited: 9
Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy
Andrew Johnsrud, Juliana Craig, John H. Baird, et al.
Blood Advances (2021) Vol. 5, Iss. 21, pp. 4465-4475
Open Access | Times Cited: 54
Idecabtagene Vicleucel (ide-cel) CAR T-cell Therapy for Relapsed and Refractory Multiple Myeloma
Larry D. Anderson
Future Oncology (2021) Vol. 18, Iss. 3, pp. 277-289
Closed Access | Times Cited: 44
Toxicities following CAR-T therapy for hematological malignancies
Rafael Hernani, Ana Benzaquén, Carlos Solano
Cancer Treatment Reviews (2022) Vol. 111, pp. 102479-102479
Closed Access | Times Cited: 32
The critical role of endothelial cell in the toxicity associated with chimeric antigen receptor T cell therapy and intervention strategies
Qi Zhang, Xiaojian Zhu, Yi Xiao
Annals of Hematology (2024) Vol. 103, Iss. 7, pp. 2197-2206
Open Access | Times Cited: 8
Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma
Pierre Sesques, Amy A. Kirkwood, Mi Kwon, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 6
Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis
Jun Meng, Xiaoqin Wu, Zhen Sun, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 39
Therapeutic Potential of TNFα and IL1β Blockade for CRS/ICANS in CAR-T Therapy via Ameliorating Endothelial Activation
Yunshuo Chen, Ranran Li, Siqi Shang, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 38
Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies
David M. Cordas dos Santos, Kai Rejeski, Michael Winkelmann, et al.
Haematologica (2022) Vol. 107, Iss. 9, pp. 2096-2107
Open Access | Times Cited: 27
Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment
Florian Schoeberl, Steffen Tiedt, Anita Schmitt, et al.
Blood Advances (2022) Vol. 6, Iss. 10, pp. 3022-3026
Open Access | Times Cited: 25
CAR t-cell therapy in BOlogNa–NEUrotoxicity TReatment and Assessment in Lymphoma (CARBON–NEUTRAL): proposed protocol and results from an Italian study
Umberto Pensato, Giulia Amore, Lorenzo Muccioli, et al.
Journal of Neurology (2023) Vol. 270, Iss. 5, pp. 2659-2673
Closed Access | Times Cited: 15
A systematic framework for predictive biomarkers in immune effector cell-associated neurotoxicity syndrome
Omar H. Butt, Alice Y. Zhou, Beau M. Ances, et al.
Frontiers in Neurology (2023) Vol. 14
Open Access | Times Cited: 13
Impact of diagnostic investigations in the management of CAR T-cell-associated neurotoxicity
Matteo Mauget, Sophie Lemercier, Quentin Quelven, et al.
Blood Advances (2024) Vol. 8, Iss. 10, pp. 2491-2498
Open Access | Times Cited: 5
Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy
Umberto Pensato, Federica Pondrelli, Chiara De Philippis, et al.
Neurological Sciences (2024) Vol. 45, Iss. 8, pp. 4007-4014
Open Access | Times Cited: 5
Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies
Xiang Zhou, Leo Rasche, K. Martin Kortüm, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 37
Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma
Raphaël Steiner, José Banchs, Efstratios Koutroumpakis, et al.
Haematologica (2021) Vol. 107, Iss. 7, pp. 1555-1566
Open Access | Times Cited: 32
Page 1 - Next Page

Scroll to top